SGMT Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.416

-16.75%

-0.410

-26.79%

-0.440

+37.5%

Estimates Revision

The market is revising No Change the revenue expectations for Sagimet Biosciences Inc. (SGMT) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -19.09%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-19.09%

In Past 3 Month

7 Analyst Rating

Wall Street analysts forecast SGMT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SGMT is 29.00 USD with a low forecast of 25.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

25.00

Averages

29.00

High

35.00

Current: 0.000

Low

25.00

Averages

29.00

High

35.00

Citizens JMP

Jonathan Wolleben

Outperform

maintain

$33 -> $35

2025-11-14

Reason

Citizens JMP

Jonathan Wolleben

Price Target

$33 -> $35

2025-11-14

maintain

Outperform

Reason

Citizens JMP analyst Jonathan Wolleben raised the firm's price target on Sagimet Biosciences to $35 from $33 and keeps an Outperform rating on the shares. Sagimet will have first-in-human data next year for the denifanstat and resmetirom combination which could be a promising option for F4 MASH patients and its next-gen FASN inhibitor TVB-3567 which could be an effective acne treatment, the analyst tells investors in a research note. Given denifanstat's potent anti-fibrotic effects in F2/F3 patients and resmetirom's non-invasive data in cirrhotics, the combination could be compelling, the firm says.

Wedbush

NULL -> Outperform

initiated

$28

2025-08-11

Reason

Wedbush

Price Target

$28

2025-08-11

initiated

NULL -> Outperform

Reason

Wedbush initiated coverage of Sagimet Biosciences with an Outperform rating and $28 price target.

H.C. Wainwright

Brandon Folkes

initiated

$29

2025-08-07

Reason

H.C. Wainwright

Brandon Folkes

Price Target

$29

2025-08-07

initiated

Reason

H.C. Wainwright analyst Brandon Folkes assumed coverage of Sagimet Biosciences with a Buy rating and $29 price target. The company is has a potential best-in-class fatty acid synthase inhibitor platform with \"multiple shots on goal\" across a number of diseases, including near-term clinical catalysts in metabolic dysfunction-associated steatohepatitis and dermatology, the analyst tells investors in a research note.

Canaccord

Edward Nash

Buy

initiated

$28

2025-07-24

Reason

Canaccord

Edward Nash

Price Target

$28

2025-07-24

initiated

Buy

Reason

Canaccord analyst Edward Nash initiated coverage of Sagimet Biosciences with a Buy rating and $28 price target.

JonesResearch

Debanjana Chatterjee

Buy

maintain

$15 -> $27

2025-06-05

Reason

JonesResearch

Debanjana Chatterjee

Price Target

$15 -> $27

2025-06-05

maintain

Buy

Reason

JonesResearch analyst Debanjana Chatterjee raised the firm's price target on Sagimet Biosciences to $27 from $15 and keeps a Buy rating on the shares. The company reported a positive readout from denifanstat's Ascletis-partnered Phase 3 acne program, the analyst tells investors in a research note. The firm says its check-in with acne doctor John Barbieri from Harvard Medical School suggests a "highly competitive profile" for FASN inhibition in acne. It now has increased confidence in the mechanism of action as well as the drug's market size.

Oppenheimer

Outperform

downgrade

$30 -> $25

2025-05-12

Reason

Oppenheimer

Price Target

$30 -> $25

2025-05-12

downgrade

Outperform

Reason

Oppenheimer lowered the firm's price target on Sagimet Biosciences to $25 from $30 and keeps an Outperform rating on the shares.

Valuation Metrics

The current forward P/E ratio for Sagimet Biosciences Inc (SGMT.O) is -3.36, compared to its 5-year average forward P/E of -2.65. For a more detailed relative valuation and DCF analysis to assess Sagimet Biosciences Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.65

Current PE

-3.36

Overvalued PE

-1.07

Undervalued PE

-4.22

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.21

Current EV/EBITDA

-0.85

Overvalued EV/EBITDA

0.48

Undervalued EV/EBITDA

-0.90

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

6.40

Current PS

0.00

Overvalued PS

38.72

Undervalued PS

-25.92

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

SGMT News & Events

Events Timeline

No data

News

7.5

01-09NASDAQ.COM

China SXT Pharmaceuticals Launches AI Initiative, Stock Rises 13.6%

9.0

2025-12-18Newsfilter

Sagimet Biosciences Advances F4 MASH Combination Therapy Development

7.5

2025-12-17SeekingAlpha

Sagimet Gains Momentum with Licensing Agreement Aimed at Madrigal Drug through Teva Unit

People Also Watch

Frequently Asked Questions

What is Sagimet Biosciences Inc (SGMT) stock price today?

The current price of SGMT is 6.21 USD — it has increased 11.49 % in the last trading day.

What is Sagimet Biosciences Inc (SGMT)'s business?

Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The Company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis. The Company is also exploring the use of its FASN inhibitors, which include denifanstat and its pipeline product candidate, TVB-3567, in acne and in select forms of cancer. Denifanstat is being tested in China by its license partner, Ascletis BioScience Co. Ltd., for moderate to severe acne vulgaris and recurrent glioblastoma multiforme in combination with bevacizumab.

What is the price predicton of SGMT Stock?

What is Sagimet Biosciences Inc (SGMT)'s revenue for the last quarter?

Sagimet Biosciences Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is Sagimet Biosciences Inc (SGMT)'s earnings per share (EPS) for the last quarter?

Sagimet Biosciences Inc. EPS for the last quarter amounts to -0.40 USD, decreased -11.11 % YoY.

What changes have occurred in the market's expectations for Sagimet Biosciences Inc (SGMT)'s fundamentals?

How many employees does Sagimet Biosciences Inc (SGMT). have?

Sagimet Biosciences Inc (SGMT) has 14 emplpoyees as of January 10 2026.

What is Sagimet Biosciences Inc (SGMT) market cap?

Today SGMT has the market capitalization of 201.96M USD.